Long Acting Suppression News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Long acting suppression. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Long Acting Suppression Today - Breaking & Trending Today

GSK's ViiV Healthcare receives approval from China's NMPA for Vocabria

GSK's ViiV Healthcare receives approval from China's NMPA for Vocabria ....

Deborah Waterhouse , National Medical Products Administration , Janssen Pharmaceutical Companies Of Johnson , Viiv Healthcare , Janssen Pharmaceutical Companies , Antiretroviral Therapy , Long Acting Suppression , First Long Acting Injectable Regimen ,

GSK : ViiV Healthcare receives approval from China's National Medical Products Administration (NMPA) for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment - Form 6-K -October 26, 2023 at 08:20 am EDT

A3337rgskplcedgar

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington,. ....

United Kingdom , United States , North Carolina , City Of , Yong Jun , United Kingdom General , Camilla Campbell , Jeff Mclaughlin , Deborah Waterhouse , Steph Mountifield , Mick Readey , Lyndsay Meyer , Nick Stone , James Dodwell , Nicola Andre , Sarah Clements , Audrey Abernathy , Rachel Jaikaran , Tim Foley , Josh Williams , Kathleen Quinn , Commission File Number , Securities Exchange , Janssen Pharmaceutical Companies Of Johnson Rekambys , China National Medical Products Administration , National Medical Products Administration ,

ViiV seeks USFDA approval to expand Cabenuva use for HIV-1 infected

ViiV Healthcare has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) to expand the use of Cabenuva. ....

Kimberly Smith , Viiv Healthcare Research , Drug Administration , Viiv Healthcare , Janssen Science , Antiretroviral Therapy , Long Acting Suppression , கிம்‌பர்லீ ஸ்மித் , ஜான்சன் அறிவியல் , ஆன்டிரெட்ரோவைரல் சிகிச்சை , நீண்டது நடிப்பு அடக்குமுறை ,

Long-acting HIV-1 treatment may remove need for daily therapy

Long-acting HIV-1 treatment may remove need for daily therapy
ViiV Healthcare has received Marketing Authorisation for the first complete long-acting injectable HIV treatment in Europe.
Marketing Authorisation has been granted by the European Commission for ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) to be used with Janssen’s Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets).
The long-acting injectable regimen was preferred by the majority of clinical trial patients who tried the treatment over their previous daily oral therapy.
ViiV Healthcare, owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi Limited as shareholders, announced the authorisation of the new treatment in the European Union (EU), for the treatment of HIV-1 infection in combination with Janssen Pharmaceutical Companies of Johnson & Johnson’s Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), in the EU, for the treatment of HIV ....

Santiago De Compostela , Janssen Rekambys , Antonio Antela , University Hospital , Pfizer Inc , European Union , European Commission For Viiv Healthcare Vocabria , Janssen Pharmaceutical Companies Of Johnson Rekambys , Viiv Healthcare , Marketing Authorisation , European Commission , Shionogi Limited , Janssen Pharmaceutical Companies , Human Immunodeficiency Virus , Positive Perspectives Wave , Antiretroviral Therapy , Long Acting Suppression , First Long Acting Injectable Regimen , Health Care Professional , ஸ்யாஂடியாகொ டி கம்போஸ்டெலா , அன்டோனியோ ஆன்டெலா , பல்கலைக்கழகம் மருத்துவமனை , ஃபைசர் இன்க் , ஐரோப்பிய தொழிற்சங்கம் , ஐரோப்பிய தரகு , ஜான்சன் மருந்து நிறுவனங்கள் ,

FDA Approves Rilpivirine, Cabotegravir as the First Long-Acting Regimen for HIV Treatment

The FDA has approved cabenuva, which consists of rilpivirine and cabotegravir, for treating HIV-1 infection in adults. This therapy is the first once-monthly, long-acting injectable to be approved for the treatment of HIV. ....

Susan Swindells , Paul Stoffels , Mathai Mammen , Department Of Internal Medicine , Janssen Research Development At Johnson , University Of Nebraska Medical Center , Viiv Healthcare , Long Acting Suppression , First Long Acting Injectable Regimen , Internal Medicine , Nebraska Medical Center , Janssen Research , மத்தாய் பாலூட்டிகள் , துறை ஆஃப் உள் மருந்து , ஜான்சன் ஆராய்ச்சி வளர்ச்சி இல் ஜான்சன் , பல்கலைக்கழகம் ஆஃப் நெப்ராஸ்கா மருத்துவ மையம் , நீண்டது நடிப்பு அடக்குமுறை , உள் மருந்து , நெப்ராஸ்கா மருத்துவ மையம் , ஜான்சன் ஆராய்ச்சி ,